Technical Analysis for VTYX - Ventyx Biosciences, Inc.

Grade Last Price % Change Price Change
D 16.97 9.77% 1.51
VTYX closed up 9.77 percent on Tuesday, December 7, 2021, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical VTYX trend table...

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish 9.77%
New Downtrend Bearish 9.77%
Lower Bollinger Band Walk Weakness 9.77%
New 52 Week Low Weakness 9.77%
Wide Bands Range Expansion 9.77%
Older End-of-Day Signals for VTYX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 10% about 12 hours ago
60 Minute Opening Range Breakout about 12 hours ago
Possible Inside Day about 12 hours ago
Rose Above Lower Bollinger Band about 16 hours ago
Up 5% about 16 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Ventyx Biosciences, Inc. Description

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Autoimmune Diseases Inflammatory Diseases Psoriasis Inflammatory Bowel Disease Ulcerative Colitis Autoimmune Disorders Lupus Cytokines Immune Mediated Diseases Molecule Product Psoriatic Arthritis

Is VTYX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.0
52 Week Low 15.12
Average Volume 237,769
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 20.44
10-Day Moving Average 19.11
Average True Range 2.41
ADX 29.29
+DI 16.13
-DI 17.11
Chandelier Exit (Long, 3 ATRs) 17.24
Chandelier Exit (Short, 3 ATRs) 22.35
Upper Bollinger Bands 24.38
Lower Bollinger Band 16.51
Percent B (%b) 0.06
BandWidth 38.46
MACD Line -0.77
MACD Signal Line -0.16
MACD Histogram -0.618
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.15
Resistance 3 (R3) 19.96 18.72 19.62
Resistance 2 (R2) 18.72 17.91 18.81 19.44
Resistance 1 (R1) 17.84 17.41 18.28 18.03 19.27
Pivot Point 16.60 16.60 16.82 16.69 16.60
Support 1 (S1) 15.72 15.79 16.16 15.91 14.67
Support 2 (S2) 14.48 15.29 14.57 14.50
Support 3 (S3) 13.60 14.48 14.32
Support 4 (S4) 13.79